Prudential Financial’s Esperion Therapeutics ESPR Stock Holding History

Prudential Financial’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$118K	Sell	37,330 -23,000	-38%	-$64.3K	﹤0.01%	2313
2026 Q1	$165K	Buy	60,330 +25,700	+74%	+$81.4K	﹤0.01%	2170
2025 Q4	$128K	Sell	34,630 -9,080	-21%	-$29.3K	﹤0.01%	2105
2025 Q3	$116K	Buy	43,710 +14,500	+50%	+$28K	﹤0.01%	2267
2025 Q2	$28.7K	Buy	29,210 +2,870	+11%	+$2.87K	﹤0.01%	2377
2025 Q1	$37.9K	Sell	26,340 -7,230	-22%	-$13.3K	﹤0.01%	2219
2024 Q4	$73.9K	Sell	33,570 -16,000	-32%	-$37.3K	﹤0.01%	2174
2024 Q3	$81.8K	Buy	49,570 +2,600	+6%	+$5.25K	﹤0.01%	2598
2024 Q2	$104K	Buy	46,970 +14,910	+47%	+$35.1K	﹤0.01%	2541
2024 Q1	$85.9K	Sell	32,060 -1,200	-4%	-$2.92K	﹤0.01%	2541
2023 Q4	$99.4K	Hold	33,260	–	–	﹤0.01%	2502
2023 Q3	$32.6K	Buy	+33,260	New	+$48.1K	﹤0.01%	2542
2020 Q1	–	Sell	-3,683	Closed	-$220K	–	2381
2019 Q4	$220K	Buy	+3,683	New	+$166K	﹤0.01%	2308

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Prudential Financial's ESPR Position: Q2 2026 in Review

Prudential Financial reduced its Esperion Therapeutics (ESPR) stake by 38% in Q2 2026, selling an estimated $64.3K and leaving 37,330 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #2313.

Prudential Financial first reported a position in ESPR in Q4 2019 and has held it in 13 quarters since. The position peaked at $220K in Q4 2019. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Prudential Financial held 37,330 shares of Esperion Therapeutics worth $118K as of Q2 2026.
Prudential Financial sold 23,000 Esperion Therapeutics shares in Q2 2026, an estimated $64.3K.
Esperion Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #2313 holding.
Prudential Financial first reported a position in Esperion Therapeutics in Q4 2019 and has held it in 13 quarters since.
Prudential Financial's Esperion Therapeutics position peaked at $220K in Q4 2019.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.